Kewajiban jangka dawa marang ekuitas: Axonics, Inc (AXNX)

Axonics, Inc. (AXNX) neuromodulator production is based on a fabless approach utilizing Asian and American plants. This chart illustrates the asset's price action, with operating profit currently at 0.26. The business depends on implant sales in clinics and the approval of new devices; meanwhile, trade conflicts and inflation are driving up electronics costs, reducing demand for elective surgeries in the US.

This ratio assesses long-term leverage by comparing liabilities with maturities exceeding one year against total equity. The metric determines the extent to which financial stability depends on borrowed funds. The current long-term debt-to-equity ratio is 0.26. Low debt leverage underscores the fundamental strength of Axonics, Inc. (AXNX). Patent protection for neuromodulators and integration with Boston Scientific make such conservatism a strategic advantage during expansion.